PA5-23585

antibody from Invitrogen Antibodies

Targeting: LAPTM5

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-23585

Provider

Invitrogen Antibodies

Product name

LAPTM5 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This antibody is predicted to react with bovine based on sequence homology.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

400 µL

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Spine‑specific downregulation of LAPTM5 expression promotes the progression and spinal metastasis of estrogen receptor‑positive breast cancer by activating glutamine‑dependent mTOR signaling.

Meng Q, Zhou L, Liang H, Hu A, Zhou H, Zhou J, Zhou X, Lin H, Li X, Jiang L, Dong J
International journal of oncology 2022 Apr;60(4)

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of NCI-H460 cells using a LAPTM5 polyclonal antibody (Product # PA5-23585) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 LAPTM5 expression is downregulated in ER + BC, especially in SM tissue. (A) A volcano plot of the data (GSE14661) was obtained from GEO datasets. Each point represents a gene. Data points highlighted in blue represent genes that are downregulated in SM tissue. The volcano plot shows that LAPTM5 expression is significantly downregulated in SM tissue compared with that in primary ER + BC tissue. (B) IHC staining of LAPTM5 in human ER + BC tissue and its tumor-adjacent normal tissue and SM tissue. (C) Quantitative analysis of the IHC results of LAPTM5 in B. (D) IHC staining of LAPTM5 in mouse ER + BC tissue, tumor-adjacent normal tissue and SM tissue. (E) Quantitative analysis of the IHC results of LAPTM5 in D. (F and G) Western blot and quantitative analysis of LAPTM5 in human ER + BC tissue, tumor-adjacent normal tissue and SM tissue. (H) qPCR results of laptm5 in mouse ER + BC and SM tissue. ** P